Brigham & Women’s Hospital – Thoracic Surgery
Harvard Medical School
Assoc. Professor – Surgery & Med.
Lung cancer is currently the number one cancer killer in the US, and thus represents a serious public health issue. Many potential surgical candidates have poor lung function and thus can only tolerate a limited surgical resection. This may leave residual malignant disease resulting in a high incidence of local tumor recurrence. Unfortunately, intravenous chemotherapy and external radiation can have severe side effects and are generally not warranted as preventative therapies.
OBJECTIVE: To develop a drug delivery platform comprised of pliable, biocompatible chemotherapy-eluting strips to be employed during surgical resection. During surgery the device will be locally-administered and deliver drug in a controlled and prolonged manner directly to the site at greatest risk for recurrent disease while also significantly diminishing the systemic toxicity associated with intravenous chemotherapy and external radiation. Furthermore, it is designed to employ instrumentation currently utilized for these procedures. The successful completion of the program promises not only extend the survival and improve the quality of life for lung cancer patients, but also to lay the foundation toward the establishment of the first standard of care for the prevention of locally recurrent lung disease following surgical resection. (read more)